L. F. Sinks

Georgetown University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Arnold I. Freeman

St. Jude Children's Research Hospital

Jun Minowada

New York State Department of Health

Shiao Y. Woo

Daegu Fatima Hospital

Tao Han

Lanzhou University Second Hospital

Martin L. Brecher

Roswell Park Comprehensive Cancer Center

T Tsubota

Okayama Prefecture

J. J. Wang

International Peace Maternity & Child Health Hospital

Sabarinath Peruvemba Subramanian

University of Nebraska Medical Center

Cameron K. Tebbi

Tampa General Hospital

ArnoldI. Freeman

University College London

Cooperative Institutions

Roswell Park Comprehensive Cancer Center

University at Buffalo, State University of New York

New York State Department of Health

Georgetown University

National Institutes of Health

Women & Children's Hospital of Buffalo

University of Washington

Georgetown University Medical Center

Children's Hospital of Los Angeles

Johns Hopkins University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Cisplatin therapy in recurrent childhood brain tumors.

PubMed (1982)

Alina Khan Bernard J. DʼSouza Moody D. Wharam Laurence Champion L. F. Sinks

Twenty-two patients with brain tumors were initially treated with surgery, radiation therapy, and/or adjuvant chemotherapy. Histologic diagnosis included 11 gliomas, seven ependymomas, one dysgerminoma, one teratocarcinoma, one pinealoma, and one small cell tumor. At recurrence, documented on computerized tomographic scan, cisplatin (60 mg/m2/day iv X 2) was given every 3-4 weeks. Seventeen patients received two or more courses and were considered to be evaluable for response. Response parameters included change in the size of tumor on computerized tomographic scan and/or in clinical findings. Four patients had complete response, five had partial response, four had stable disease, and four had disease progression. Toxic effects were manageable. The number of patients with grade 3-4 toxic reactions, by category, were: thrombocytic, ten; leukocytic, four; renal, five; metabolic, four; gastrointestinal, none; and neurologic, seven. Two of the 14 patients tested had grade 3-4 ototoxicity. Acute fluid retention with decreased serum electrolytes and serious but reversible changes in the mental status, which were experienced in earlier patients, decreased in severity with increasing experience of the investigator. In summary, cisplatin appears to be active in a spectrum of brain tumors and should be studied further for therapeutic efficacy.

Brain tumor

Pinealoma

Source

Cite

Citations (100)

The Treatment of Wilms' Tumor.

CRC Press eBooks (2023)

D'Angio Gj A. Evans N. E. Breslow Bruce Beckwith H Bishop

The National Wilms' Tumor Study (NWTS), initiated in 1969, tested competing treatment strategems for patients with tumours ranging from Group (Gp) I to Gp IV. This chapter presents and discusses the frequency of mesoblastic nephroma, of bilateral tumours, and of incorrect preoperative diagnosis of Wilms' tumor, the toxicities of the various regimens and other ancillary data. The evolution of the multimodal modern management of Wilms' tumor is one of the success stories of contemporary paediatric surgery, and due credit is rightly given to the American NWTS and Societe Internationale D'oncologie Pediatrique, its European equivalent, in designing and carrying out big clinical trials. The treatment was well tolerated in all age groups. However, there were ten treatment-related mortalities amongst the 359 children treated. Six of these deaths were in children receiving intense treatment after a relapse of the primary tumour.

10.1201/b23252-36

Cite

Citations (0)

Hodgkin's disease in children

Medical and Pediatric Oncology (1976)

Nirja Shah Arnold I. Freeman Moshe Friedman Leon Stutzman John F. Gaeta

Abstract From 1921 to 1973, 106 children with Hodgkin's disease under the age of 17 years were seen at Roswell Park Memorial Institute and were analyzed retrospectively. Evaluation was separated into three eras: 1921–1949 (early era), 1950–1964 (middle era), and 1965–1973 (recent era). In the early era, suboptimal radiation therapy was employed. In the middle era, radiation therapy techniques were improved, and single‐agent chemotherapy was introduced. In the recent era, multiagent chemotherapy routines were frequently used; aggressive external megavoltage radiation therapy became routine in conjunction with improvement in staging procedures. The best survival was observed in the recent era where five‐year survival of 96% was noted in early stage disease. Favorable prognostic features included: younger age group (5–9 years), female sex, lymphocytic predominant histology, early stage disease, and complete response to therapy. Nodular sclerosing and mixed cell types had an equal prognosis. The concept of involved area radiotherapy along with combination chemotherapy appears a reasonable approach in children and should be tested in a randomized study against more extensive radiotherapy techniques in early stage disease.

10.1002/mpo.2950020110

Cite

Citations (9)

Adjuvant adriamycin and cisplatin in newly diagnosed, nonmetastatic osteosarcoma of the extremity.

Journal of Clinical Oncology (1986)

Lawrence J. Ettinger H. O. Douglass Eugene R. Mindell L. F. Sinks Cameron K. Tebbi

Twenty-two patients with newly diagnosed nonmetastatic osteosarcoma of the extremity were treated with an adjuvant chemotherapeutic regimen consisting of Adriamycin (Adria Laboratories, Columbus, Ohio) and cisplatin. Fourteen of the 22 patients remain continuously disease free for 65+ to 113+ months, with a median time on study of 70+ months. The 72-month disease-free survival estimate is 64%. Pulmonary metastases occurred in six patients, an isolated stump recurrence was seen in one patient, and one patient had a local recurrence following a limb-salvage procedure. For those patients in whom pulmonary metastases developed, the onset was late in three of six, and the number of metastases was three or fewer in all patients. Two patients with pulmonary metastases and one with a stump recurrence have apparently been salvaged, thus resulting in a 77% 72-month survival. Toxicity observed in patients treated with this regimen was in keeping with previous reports. This chemotherapeutic regimen is effective in the adjuvant therapy of nonmetastatic osteosarcoma of the extremity. It should be incorporated into other adjuvant protocols in an effort to continue to improve the outcome in patients with osteosarcoma.

Regimen

Adjuvant Therapy

Adjuvant Chemotherapy

10.1200/jco.1986.4.3.353

Cite

Citations (33)

Kinetics of Rapidly Labelled RNA in Human Leukaemia Cells

British Journal of Haematology (1966)

L. F. Sinks F. G. J. Hayhoe

T he kinetics of rapidly labelled RNA have been studied autoradiographically in several mammalian cell types, including, among cells of human origin, Hela cells (Feinendegen, Bond, Shreeve and Painter, 1960), PHA (phytohaemagglutinin)‐induced blast cells (Hayhoe and Quaglino, 1965) and various mononuclear cells of peripheral blood (Storti and Torelli, 1965). Early work with labelled RNA precursors in leukaemic cells (Gavosto, Maraini and Pileri, 1960) showed that uptake was much diminished as compared with that of normal immature cells of the haemopoietic system, and later chase studies of movement of label from nucleus to cytoplasm, while confirming the generally low percentage of uptake, suggested that the nuclear‐cytoplasmic shift was sometimes delayed (Quaglino and Hayhoe, 1965). Again, Storti and Torelli (1965) have presented evidence that in at least some cases of acute leukaemia the labile, rapidly degraded, fraction of RNA, which may well have messenger function, is either absent or metabolically different from that of normal leucoblasts. It is clearly of great importance to explore the patterns of RNA kinetics in leukaemic cells and to determine whether the time sequence of movement of label from nucleus and nucleolus to cytoplasm and the types of RNA formed do in fact differ substantially from those of normal haemopoietic precursors or such a model cell system as is provided by PHA‐induced blast cells. As a first step we have therefore carried out a series of chase experiments in ten leukaemic cases to study the intracellular movement of a potential RNA label and to establish whether a constant pattern exists.

Phytohaemagglutinin

HeLa

10.1111/j.1365-2141.1966.tb00163.x

Cite

Citations (4)

The Treatment of Primary Childhood Acute Lymphocytic Leukemia with Intermediate Dose Methotrexate

Hämatologie und Bluttransfusion (1981)

L. F. Sinks J. J. Wang ArnoldI. Freeman

White blood cell

Acute lymphocytic leukemia

Prophylactic cranial irradiation

10.1007/978-3-642-67984-1_15

Cite

Citations (6)

Treatment of acute lymphoblastic leukaemia.

Archives of Disease in Childhood (1972)

L. F. Sinks

Acute lymphocytic leukemia

10.1136/adc.47.255.811

Cite

Citations (18)

The elekctrokinetic surfaces of human cells of lymphoid origin and their ribonuclease susceptibility.

PubMed (1970)

L. Weiss L. F. Sinks

Summary A comparison has been made of the electrophoretic mobilities of human peripheral lymphocytes, peripheral malignant cells from patients with acute and chronic leukemia, cultured “normal” lymphoblasts, and cultured cells derived from Burkitt9s tumors. No consistent differences were observed between the electrophoretic mobilities of the isolated but otherwise untreated cells. However, following incubation of the cells with ribonuclease A, their electrophoretic mobilities fell into two groups. The net surface negativity of the normal peripheral lymphocytes and cultured “normal” lymphoblasts were significantly reduced by exposure to the enzyme, whereas the surface negativity of the peripheral leukemic cells and the cultured cells derived from Burkitt tumors was not. These findings of different ribonuclease susceptibility may not be readily correlated with cell proliferation and may indicate surface differences between normal and malignant cells of lymphoid origin.

Lymphoblast

Negativity effect

Source

Cite

Citations (14)

High-dose methotrexate in acute lymphocytic leukemia.

PubMed (1977)

Arnold I. Freeman J-J Wang L. F. Sinks

A pharmacokinetic study of methotrexate (MTX) was performed in 60 patients who received high-dose MTX at 500 mg/m2 infused over 24 hours. MTX levels reached 1.2 X 10(-7) M in the cerebrospinal fluid (CSF) within 10 minutes and remained constant at that level for 24 hours. Forty of these 60 patients were children with acute lymphocytic leukemia. In these 40 patients, simultaneous intrathecal MTX was given along with high-dose MTX. The resultant CSF levels (lumbar area) were higher than those obtained with either high-dose MTX alone or simultaneous intrathecal MTX alone. To date, there have been one systemic and one central nervous system relapse in these 40 children, and the treatment program appears safe to administer.

Acute lymphocytic leukemia

Intrathecal

Antifolate

Source

Cite

Citations (63)

Controlled Clinical Trials in Leukemia in Children

Springer eBooks (1973)

L. F. Sinks

10.1007/978-1-4684-2070-8_32

Cite

Citations (2)